CAR-T development

CAR-T development

Publication date : 2019-10-01

Diaclone continues its implication in innovative health technology with its participation in the development of IL-1RAP CAR T cells (Warda W Cancer Res February 1 2019 79 (3) 663-675) and in a CD123 CAR T cells project (both in collaboration with the INSERM U1098 research team in Besançon, France).

Diaclone is renowned as a specialist in antibody development - in particular CD markers and membrane expressed proteins. Diaclone’s competence in cell biology and antibody development coupled with its new molecular biology platform and the antibody engineering capabilities of the mAbexperts team ( can provide:

  • Development of monoclonal antibodies against a target
  • Platform for bioassays and Ab characterisation
  • mAb sequencing, ScFv and transgene construction
  • Tools for controls: Kits, Antibodies and recombinant proteins (IL-2, TNF-a, ...)
Find out more...

Other news

  • New Diaclone Catalogue!
    New Diaclone Catalogue
    Publication date : 2019-09-05
    Diaclone is pleased to present its new catalogue! Just click and discover.... Read more
  • Diaclone est partenaire d’un projet européen d’envergure associant une douzaine de partenaires de la région de Besançon.
    MiMédi Project
    Publication date : 2019-08-29
    Diaclone is a partner in a major European project involving a dozen partners from the Besançon region. Read more
  • Assays for the Human IL-17 Family
    DIACLONE Assays for the Human IL-17 Family
    Publication date : 2019-08-28
    Diaclone has developed a large range of ELISA and ELISpot kits for the detection of Human IL-17A, IL-17F and IL-17A/F. Read more
  • PSL
    PSL Alliance
    Publication date : 2019-08-28
    Diaclone is a core member of the PSL Alliance Read more
    The CAM family: A new target for monitoring or treating cancers?
    Publication date : 2019-08-28
    The cell adhesion molecules (CAMs) family includes more than 50 proteins with four main groups: immunoglobulin (Ig)-like CAMs, cadherins, selectins, and integrins. Read more
  • Smaltis
    SMALTIS joins the Biotech Investissement Group!
    Publication date : 2019-08-28
    We are pleased to announce the entry of Biotech Investissement into the capital of SMALTIS SAS, a company based in Besançon (France), which joins RD-Biotech SAS, Diaclone SAS, SynAbs SA and QVQ Holding within the group ( Read more

Product search